These can be considered “NK cell adaptors”; they usually target an activating receptor, like NKp46 and CD16 on NKs and a tumor antigen, such as CD19, CD20, or endothelial growth factor receptor (EGFR) and Fc fragments (138). This evidence concerns the gene EGFR and neoplasm.